Publications by the researcher in collaboration with Elisa Luño Fernández (10)

2020

  1. miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk

    Leukemia, Vol. 34, Núm. 10, pp. 2648-2659

2017

  1. Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group

    Leukemia Research, Vol. 63, pp. 85-89

  2. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R)

    American Journal of Hematology, Vol. 92, Núm. 7, pp. 614-621

2016

  1. Considering bone marrow blasts from nonerythroid cellularity improves the prognostic evaluation of myelodysplastic syndromes

    Journal of Clinical Oncology, Vol. 34, Núm. 27, pp. 3284-3292

  2. Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: A rationale for its inclusion into future classifications of myelodysplastic syndromes

    Modern Pathology, Vol. 29, Núm. 12, pp. 1541-1551

2015

  1. Trisomy 8, a cytogenetic abnormality in myelodysplastic syndromes, is constitutional or not?

    PLoS ONE, Vol. 10, Núm. 6

2014

  1. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion

    British Journal of Haematology, Vol. 166, Núm. 2, pp. 189-201

  2. Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis

    Leukemia Research, Vol. 38, Núm. 3, pp. 304-309

2011

  1. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response

    Current Medical Research and Opinion, Vol. 27, Núm. 5, pp. 951-960

2009

  1. P030 Prognostic impact on survival of an unsuccessful conventional cytogenetic study in patients with myelodysplastic syndromes (MDS)

    Leukemia Research, Vol. 33, Núm. SUPPL. 1